Spero Therapeutics (SPRO) Payables (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Payables came in at $217000.0 in Q1 2026, down 87.71% YoY from $1.8 million in Q1 2025, and down 68.69% on a QoQ basis from $693000.0 in Q4 2025.
Spero Therapeutics (SPRO) Payables (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Payables data on file, last reported at $217000.0 in Q1 2026.
- Quarterly Payables fell 87.71% year-over-year to $217000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217000.0 (down 87.71% YoY) and the FY2025 annual result came in at $693000.0, down 90.51% from the prior year.
- Payables fell to $217000.0 in Q1 2026, from $693000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $7.3 million in Q4 2024 to a low of $217000.0 in Q1 2026.
- A 5-year average of $2.3 million and a median of $1.4 million in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2024 — Payables surged 452.13% — and 2025, when it sank 90.51%.
- Tracing SPRO's Payables over 5 years: stood at $617000.0 in 2022, then soared by 123.34% to $1.4 million in 2023, then jumped by 430.19% to $7.3 million in 2024, then sank by 90.51% to $693000.0 in 2025, then sank by 68.69% to $217000.0 in 2026.
- The last three Payables figures came in at $217000.0 (Q1 2026), $693000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 155,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 155,000.00 |
| Mar 31, 2026 | 217,000.00 |
| Dec 31, 2025 | 693,000.00 |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 780,000.00 |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 7.31 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 583,000.00 |
| Dec 31, 2022 | 617,000.00 |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 1.83 Mn |
| Mar 31, 2022 | 5.78 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Sep 30, 2021 | 3.16 Mn |